Ipragliflozin , 97% , 761423-87-4
| Pack Size | Price | Stock | Quantity |
| 10mg | RMB95.20 | In Stock |
|
| 25mg | RMB159.20 | In Stock |
|
| 100mg | RMB439.20 | In Stock |
|
| 500mg | RMB1519.20 | In Stock |
|
| 1G | RMB2239.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 155-157°C |
| Boiling point: | 628.8±55.0 °C(Predicted) |
| Density | 1.452 |
| storage temp. | Refrigerator |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| pka | 13.27±0.70(Predicted) |
| form | Solid |
| color | White to Off-White |
Description and Uses
Ipragliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50 = 7.4 nM in CHO cells expressing the human cotransporter). It is selective for SGLT2 over SGLT1, SGLT3, SGLT4, SGLT5, and SGLT6 (IC50s = 1.9, 30.4, 15.9, 0.46, and 10.4 μM, respectively). Ipragliflozin (0.1-3 mg/kg) decreases plasma levels of insulin and glucose in an oral glucose tolerance test in a mouse model of diabetes induced by high-fat diet, streptozotocin (STZ; ), and nicotinamide . It decreases plasma and hepatic IL-6, TNF-α, chemokine (C-C motif) ligand 2 (CCL2), and C-reactive protein (CRP) levels in the same model when administered at a dose of 3 mg/kg per day for 28 days.
Ipragliflozin is a potent and selective inhibitor of sodium-glucose cotransporter-2 (SGLT2) and can serve as a potential agent for the treatment of type 1 and type 2 diabetes.
